AI-Driven Precision Testing for Cancer Care
Waiv, a Paris-based company spun out from Owkin, just raised $33 million to take its AI precision testing platform global. OTB Ventures and Alpha Intelligence Capital led the round, with Serena Data Ventures, Karista, and SistaFund joining in.
Waiv stands on ten years of Owkin’s AI research, turning everyday clinical and histopathology data into ready-to-use precision tests. Their platform gives labs, doctors, and drug developers insights they can actually use. Tools like RlapsRisk BC, MSIntuit Suite, and BRCAura deliver results in minutes.
That means doctors can sort patients faster and make treatment decisions sooner. The best part? Labs don’t need to overhaul their systems—Waiv just fits in and makes precision medicine more accessible. Cancer care has gotten incredibly complex. Patients show up with multiple biomarkers, and pulling together biological, genomic, and care data really matters now.
The old way—traditional diagnostics—just can’t keep up. It’s slow and all over the place. Waiv changes that. Its AI-driven tests are quick, accurate, and scalable, giving patients faster, more personalized care. Researchers also get solid data, making it easier to run and optimize clinical trials.
Advanced AI Platform and Pharma Integration
Waiv’s platform brings together its own AI models, multimodal analytics, and data from the PortrAIt consortium—one of Europe’s biggest multi-institutional precision medicine datasets. Their Destra platform plugs right into existing lab systems, so labs can use all of Waiv’s tests without overhauling their IT. It’s smooth, quick, and fits into almost any clinical setting.
Waiv works with top pharma companies to speed up drug development. Some standout projects include BRCAura, which uses AI for gBRCA pre-screening, and a collaboration with MSD to spot MSI-enriched groups. These partnerships make clinical trials more efficient, help match patients to the right treatments faster, and push personalized medicine forward.
Karol Szubstarski from OTB Ventures pointed out that Waiv can turn routine pathology slides into detailed disease maps. Arnaud Barthélémy from Alpha Intelligence Capital said Waiv’s AI platform scales easily, improves how labs predict outcomes and detect biomarkers, and actually makes a difference in clinical results worldwide.
Transforming Diagnostics with AI
Waiv’s AI-driven platform streamlines cancer diagnostics, accelerating treatment decisions and lab efficiency. Source: Created by Ventureburn.
Cancer diagnosis isn’t simple. Doctors need to pull together all kinds of data—histopathology slides, patient records, biomarker results—just to make the right call on treatment. But old-school systems can’t really handle all those moving pieces at once, which slows everything down and holds back precision medicine.
That’s where Waiv steps in. Instead of just scanning pathology slides, Waiv turns routine lab data and other info into ready-to-use AI tests for everyday clinics. You get quick answers about things like gBRCA mutations and MSI markers, no next-gen sequencing required.
Labs can roll out these AI-powered tests without ripping out their old IT systems, so everyone can work together at scale, no hassle. Fabrice André from Gustave Roussy points out that tools like RlapsRisk BC are now reaching more patients than ever, making a real difference in both outcomes and how smoothly everything runs. Waiv really cuts down on manual work and shaves time off the whole process.
Basic compliance checks and validation? Automated. That means staff can finally focus on decisions that matter most. Thanks to its speed, accuracy, and audit trails, labs can ramp up operations without missing a beat. Drug developers and clinicians get the info they need to plan the best treatments, and patients benefit from smarter, faster care.
More News: Qurrent Raises $15M to Expand Autonomous Digital Workforces
Global Expansion and Future Development
Waiv just secured $33 million in funding, and they’re wasting no time putting it to work. The team plans to roll out more clinical-grade tests, build tighter partnerships with pharma companies, and bring their technology to more countries.
They’re also beefing up the PortrAIt consortium, making sure their datasets don’t just represent one group but reflect real-world diversity. That way, their AI actually works for everyone, not just a select few. And for labs, Waiv’s Destra platform means you can start using these tests right away—no massive IT overhaul needed. That’s a big deal for global expansion.
CEO Meriem Sefta gets right to the point: precision medicine only works when you match patients to the right treatments. Waiv’s AI doesn’t just keep up—it scales, delivering faster, more reliable results for cancer diagnostics.
Their proprietary models and multimodal analytics keep performance steady, no matter where you are. Plus, because they’re always running clinical validation, accuracy doesn’t slip. The platform isn’t just about diagnostics. It helps with biomarker discovery and making sure clinical trials are ready to go, paving the way for more personalized therapies.
By bringing together AI, pathology, and advanced analytics, Waiv makes it easier for pharma companies and healthcare providers to work together. Labs can run advanced precision tests at scale, and patients get quicker, more tailored treatment options.
With this new funding, Waiv is set to launch more tests, forge deeper pharma partnerships, and drive global adoption. They’re not just following the pace of change in cancer care—they’re setting it, pushing AI-powered precision testing toward becoming the worldwide standard.
To stay updated on crypto venture capital funding and market trends, visit our venture capital news section for more insights.
